Cumberland Pharmaceuticals (NASDAQ:CPIX) Cut to “Buy” at Wall Street Zen

Cumberland Pharmaceuticals (NASDAQ:CPIX) was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Monday.

Cumberland Pharmaceuticals Price Performance

Shares of NASDAQ:CPIX opened at $3.29 on Monday. The company has a 50 day moving average of $3.48 and a 200 day moving average of $4.45. The stock has a market cap of $49.22 million, a P/E ratio of -14.95 and a beta of -0.39. Cumberland Pharmaceuticals has a 12 month low of $1.04 and a 12 month high of $7.25. The company has a current ratio of 1.30, a quick ratio of 1.17 and a debt-to-equity ratio of 0.19.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last issued its quarterly earnings data on Tuesday, August 5th. The specialty pharmaceutical company reported $0.02 EPS for the quarter. Cumberland Pharmaceuticals had a negative net margin of 6.97% and a positive return on equity of 7.48%.

Institutional Investors Weigh In On Cumberland Pharmaceuticals

Several hedge funds have recently bought and sold shares of CPIX. XTX Topco Ltd bought a new stake in Cumberland Pharmaceuticals during the second quarter valued at approximately $34,000. Two Sigma Investments LP raised its holdings in Cumberland Pharmaceuticals by 94.3% during the 4th quarter. Two Sigma Investments LP now owns 37,649 shares of the specialty pharmaceutical company’s stock valued at $89,000 after buying an additional 18,271 shares during the last quarter. Heron Bay Capital Management bought a new stake in Cumberland Pharmaceuticals during the 2nd quarter valued at $111,000. Walleye Capital LLC purchased a new position in Cumberland Pharmaceuticals during the 1st quarter valued at $298,000. Finally, Informed Momentum Co LLC purchased a new position in Cumberland Pharmaceuticals during the 1st quarter valued at $304,000. 15.51% of the stock is currently owned by institutional investors.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.